GALENIKA LAUNCHES THERAPY FOR OBESITY TREATMENT
Belgrade, March 2, 2026 – In response to the dramatic rise in obesity and related chronic diseases, Galenika has made a strategic step forward through a partnership with its sister company EMS from Brazil, introducing a next-generation therapy and reaffirming its role as a regional leader in modern pharmaceuticals.
At a time when obesity is reaching the scale of a global epidemic, Galenika is launching a new era in the fight against obesity by introducing a modern GLP-1 therapy, opening a new chapter in the prevention and treatment of 21st-century diseases.
With the growing prevalence of diabetes, cardiovascular, and metabolic diseases, the need for advanced therapeutic solutions has never been greater. By strategically entering the GLP-1 therapy segment, pharmaceutical company Galenika positions itself at the center of one of the most dynamic and promising areas of contemporary medicine, responding to increasing healthcare and market demands. With this therapeutic solution in the field of metabolism, the company strengthens its portfolio and confirms its long-term strategy focused on innovation and development in segments with the greatest medical and economic potential.
Today, we are not only presenting a new therapy within our portfolio, but also a new perspective in the fight against one of the most widespread diseases of the modern era. Obesity requires a systemic, responsible, and long-term public health approach. By launching GLP-1 therapy, Galenika confirms its commitment to providing patients in Serbia and the region with modern and effective therapeutic options. We believe this marks the beginning of a transformation in how we approach obesity treatment — moving away from stigmatization toward a scientifically grounded, comprehensive, and humane approach,” said Rikardo Vian Marques, General Manager of Galenika.
Obesity today represents a global epidemic. According to data from leading international health organizations, the number of people living with overweight and obesity continues to grow, while the consequences of this trend are placing an increasing burden on healthcare systems worldwide. Serbia is no exception — the percentage of adults and children affected by obesity is steadily rising, increasing the risk of developing serious chronic diseases.
Aware of its responsibility and role as one of the regional pharmaceutical leaders, Galenika is introducing a therapy aimed at creating a more sustainable treatment model, particularly in light of rising healthcare system costs caused by obesity and related diseases. Obesity is a chronic, complex disease that significantly increases the risk of type 2 diabetes, cardiovascular disease, hypertension, stroke, certain types of cancer, and numerous other metabolic disorders. The fight against obesity is therefore a fight for a longer, higher-quality, and healthier life.
Galenika’s therapeutic solution is based on modern scientific achievements that are transforming the approach to obesity treatment. GLP-1 therapy works by regulating appetite and metabolism, providing patients with support in achieving and maintaining a healthy body weight under professional medical supervision. GLP-1 therapy is redefining obesity treatment worldwide.
With this strategic move, Galenika further strengthens its position as a company that continuously invests in innovation, follows global trends, and recognizes the needs of modern society. The new therapy is part of the company’s broader vision focused on improving quality of life and strengthening public health.
The fight against obesity requires partnership among healthcare institutions, physicians, patients, and the pharmaceutical industry, and Galenika is ready to be a reliable partner in that fight — today and in the future.
***
Pharmaceutical company Galenika (www.galenika.com) was founded in 1945. At the end of 2017, it became part of the NC Group (www.gruponc.net.br), which also includes EMS – the largest pharmaceutical company in Brazil and one of the largest pharmaceutical companies in the Latin America. With a portfolio of over 330 products, Galenika manufactures generic drugs, dietary supplements, cosmetic products and medical devices. The Group’s strategy is the development of Galenika as a modern and flexible company, focused on research and development, which constantly works on expanding its portfolio to enhance health and quality of life.